MACRA : “A” is for Access and “C” is for Children
MACRA's vision is that early interventions with children are key to reduce costly chronic diseases later in life. For this to work, education, access and health data interoperability are imperative.

MACRA : “A” is for Access and “C” is for Children

MACRA Changes Health Care Economics with a Focus on ChildrenMACRA Background: A final rule released on Oct. 14, 2016 by the Centers for Medicare and Medicaid Services (CMS) details the final…

Continue Reading MACRA : “A” is for Access and “C” is for Children

Value Based Insurance Design New Clinical Categories for MA Plans

The Centers for Medicare & Medicaid Services (CMS) is announcing refinements to the Medicare Advantage Value-Based Insurance Design (MA-VBID) model. Beginning January 1, 2018, CMS will add rheumatoid arthritis and dementia…

Continue Reading Value Based Insurance Design New Clinical Categories for MA Plans

CMS Moves forward with CPC+ that Includes PMPM to PCPs

According to CMS, the Original Comprehensive Primary Care (Original CPC) Model, is being replaced with the Comprehensive Primary Care Plus (CPC+) which is intended to allow health care provider practices to apply for one of two program tracks, with increasing payment and care redesign expectations from Tracks 1 to 2.

Continue Reading CMS Moves forward with CPC+ that Includes PMPM to PCPs

CMS Merit Based Incentive Payment System (MIPS) in 60 Day Comment Period, Sunsetting of Meaningful Use

New Federal healthcare industry payment models, based on the April 27th release of a proposed rule, present MIPS, MACRA, and APM methods for calculating healthcare reimbursement. The document proposes once…

Continue Reading CMS Merit Based Incentive Payment System (MIPS) in 60 Day Comment Period, Sunsetting of Meaningful Use

Drug Pricing Legislation and Inefficient Markets Theory

The inefficient markets theory is being reconsidered after the 2007 financial crisis in the U.S. Is it enough to provide the public with data on the cost of a service or alternative ways to purchase it? In healthcare the intersection of price, quality and sources of suppliers alone does not determine whether pricing is appropriate.

Continue Reading Drug Pricing Legislation and Inefficient Markets Theory